Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,044 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glial Tumor of Brain Clear all
Not listed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00014105
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, temozolomide
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 7, 2026, 10:35 AM EDT
Active, not recruiting Not applicable Interventional

Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue

NCT04545177
View directory record Official record
Conditions
Glioblastoma
Interventions
NICO Myriad and Tissue Preservation System (TPS)
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Brain Tumors

NCT00003457
View directory record Official record
Conditions
Refractory Brain Tumors
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 7, 2026, 10:35 AM EDT
Terminated Phase 4 Interventional

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

NCT01756729
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

NCT00019019
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 7, 2026, 10:35 AM EDT
Completed No phase listed Observational

C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors

NCT05984667
View directory record Official record
Conditions
Glioma, Mixed, Mild Neurocognitive Disorder, Brain Tumor
Interventions
C-SMART
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

NCT01158300
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
VEGF inhibitor PTC299
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide

NCT00616005
View directory record Official record
Conditions
Glioblastoma
Interventions
Temodar and Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

NCT01985256
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
Interventions
Toca 511, Toca FC
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404

NCT01540513
View directory record Official record
Conditions
Glioblastoma Multiforme, Brain Metastases
Interventions
NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

NCT00058370
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, lomustine, vincristine sulfate, adjuvant therapy, iodine I 131 monoclonal antibody 3F8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 7, 2026, 10:35 AM EDT
Terminated Not applicable Interventional

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02967380
View directory record Official record
Conditions
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Primary Melanocytic Lesion of Meninges, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma, Metastatic Malignant Neoplasm in the Brain, Multiple Sclerosis, Recurrent Adult Brain Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol, Gadopentetate Dimeglumine
Procedure · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

NCT00003293
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
leflunomide, procarbazine hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Oct 7, 2026, 10:35 AM EDT
Terminated Phase 2 Interventional Results available

Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00052715
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
poly ICLC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT00003876
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
polifeprosan 20 with carmustine implant, surgical procedure, iodine I 125
Drug · Procedure · Radiation
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 7, 2026, 10:35 AM EDT
Terminated Early Phase 1 Interventional

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

NCT02500459
View directory record Official record
Conditions
Brain Tumor, High Grade Glioma
Interventions
topotecan, Cleveland Multiport Catheter
Drug · Device
Lead sponsor
Michael Vogelbaum, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 7, 2026, 10:35 AM EDT
Terminated Phase 2 Interventional

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

NCT00730262
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TLN-4601
Drug
Lead sponsor
Thallion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

NCT00883688
View directory record Official record
Conditions
Brain Cancer, Pediatric Cancers
Interventions
Bevacizumab, Lapatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 7, 2026, 10:35 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib in Sarcomas of the Central Nervous System

NCT03641326
View directory record Official record
Conditions
Gliosarcoma, Central Nervous System Sarcoma
Interventions
Sunitinib, wGT3x-BT
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 7, 2026, 10:35 AM EDT
Withdrawn Phase 2 Interventional

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

NCT03632317
View directory record Official record
Conditions
Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Panobinostat, Everolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
2 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

NCT00025558
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, temozolomide, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas

NCT00042991
View directory record Official record
Conditions
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligodendroglioma
Interventions
gefitinib, radiation therapy, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 1Phase 2 Interventional

Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors

NCT00005952
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, temozolomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
Up to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 7, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme

NCT00003464
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 7, 2026, 10:35 AM EDT